Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Southern Company (SO) Price & Performance

GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.

The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.

Southern Company (SO) trades at $88.11, up 1.23% on the day, with a mixed technical outlook showing a bullish overall signal but bearish oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with Q3 2026 results pending. Revenue and net income are projected to grow in 2026, supported by a 15.43% net income margin. Analyst sentiment is cautious with a 32.35% buy rating, but the consensus price target of $96.38 suggests upside potential. Recent news highlights data center demand and dividend stability, though near-term cash flow pressure from high capital expenditures is a concern.

The outlook for SO is balanced, with long-term growth driven by utility demand and data center contracts, but near-term risks include capital expenditure pressures and potential data breach impacts. The stock offers a stable dividend and is positioned for gradual appreciation if earnings continue to outperform, yet investors should monitor cash flow trends and regulatory developments.